Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Drug monograph
Not yet extracted
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Dangerous ventricular arrhythmia (QT prolongation, torsades de pointes)
Concurrent use is contraindicated
Source: KDT 7e · p948
Increased risk of cardiac conduction defects.
Source: KDT 7e · p816-835
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Life-threatening QT prolongation.
Aprepitant is contraindicated in patients receiving astemizole.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team